Diabetes Mellitus Case Study

Introduction

Diabetes mellitus is a chronic, metabolic disease characterized by persistent hyperglycemia that damages multiple organ systems over time. According to the World Health Organization (WHO), the global burden of diabetes has increased dramatically; the number of people living with diabetes rose from 200 million in 1990 to 830 million in 2022[1]. Over half of individuals with diabetes do not receive treatment, especially in low and middle‑income countries[2]. Hyperglycemia is associated with complications such as blindness, kidney failure, heart attacks, stroke and lower‑limb amputations[3]. Lifestyle factors unhealthy diet, physical inactivity, obesity and tobacco use contribute significantly to the development of type 2 diabetes mellitus (T2DM), which accounts for more than 95 % of all diabetes cases[4]. The following case study presents an in‑depth analysis of a patient with T2DM, including pathophysiology, risk factors, complications, diagnosis, treatment and nursing management. The goal is to integrate evidence‑based practice with patient centered care and illustrate how nurses play a critical role in managing chronic diseases like diabetes.

Background and Pathophysiology of Diabetes Mellitus

Classification and Epidemiology

Diabetes mellitus comprises several types:

Type 1 diabetes is characterized by autoimmune destruction of pancreatic β‑cells, leading to absolute insulin deficiency. It often presents in childhood or adolescence but can occur at any age. Individuals require lifelong insulin therapy to survive[5].
Type 2 diabetes results from a progressive loss of adequate β‑cell insulin secretion in the context of chronic insulin resistance. It typically develops in adulthood but increasingly affects younger populations and children due to rising obesity and sedentary lifestyles[6]. More than 95 % of people with diabetes have T2DM[7].
Gestational diabetes occurs during pregnancy and increases the risk of maternal and fetal complications and later development of T2DM[8].
Prediabetes and impaired glucose tolerance represent intermediate stages between normal glycemia and diabetes, indicating elevated risk for progressing to T2DM[9].

The global prevalence of diabetes has been rising rapidly: adults aged ≥18 years living with diabetes increased from 7 % in 1990 to 14 % in 2022[10]. Diabetes causes millions of deaths annually and contributes significantly to cardiovascular mortality[11]. The economic burden includes direct medical costs and loss of productivity, making diabetes a public health priority.

Pathogenesis of Type 2 Diabetes Mellitus

The pathophysiology of T2DM is multifactorial and complex. Insulin resistance and β‑cell dysfunction are central features[12]. In insulin‑resistant states, skeletal muscle and adipose tissues fail to respond adequately to insulin, leading to decreased glucose uptake. The liver continues to produce glucose despite hyperglycemia, contributing to augmented endogenous glucose production[13]. Adipose tissue insulin resistance results in increased lipolysis and elevated free fatty acids, further impairing glucose utilization and β‑cell function[14].

Over time, β‑cell compensatory mechanisms fail. Chronic exposure to high glucose and lipids referred to as glucotoxicity and lipotoxicity damages β‑cells, resulting in reduced insulin secretion[15]. Inappropriate glucagon secretion from pancreatic α‑cells exacerbates hyperglycemia and is partly attributed to an incretin defect diminished secretion or action of hormones such as GLP‑1 and GIP[16]. The gut microbiome, hypothalamic insulin resistance, increased renal glucose reabsorption and genetic/epigenetic factors also contribute to T2DM pathophysiology[17].

Pathogenesis of Microvascular and Macrovascular Complications

Chronic hyperglycemia leads to vascular damage through several biochemical pathways. For microvascular complications, hyperglycemia induces activation of the polyol pathway, formation of advanced glycation end‑products (AGEs), increased flux through the hexosamine pathway, protein kinase C activation, oxidative stress and inflammation[18]. These changes damage capillaries and small vessels, causing diabetic retinopathy, nephropathy and neuropathy[19]. Emerging research highlights the roles of long non‑coding RNAs, extracellular matrix accumulation and abnormal neovascularization in diabetic nephropathy and retinopathy[20]. Macrovascular complications such as coronary artery disease, cerebrovascular disease and peripheral arterial disease result from endothelial dysfunction, oxidative stress, dyslipidemia and accelerated atherosclerosis[21].

Diabetic Nephropathy

Diabetic nephropathy, now often termed diabetic kidney disease (DKD), is the leading cause of end‑stage renal disease[22]. Pathologically, DKD is characterized by glomerular hypertrophy, thickening of the basement membrane, podocyte loss and mesangial expansion[23]. Hyperglycemia generates reactive oxygen species and activates pathways involving AGEs, nuclear factor κB, protein kinase C and transforming growth factor‑β, leading to renal fibrosis and progressive decline in glomerular filtration rate[24]. Early detection through albuminuria assessment and aggressive management of glycemic and blood pressure control can delay progression[25].

Diabetic Retinopathy

Diabetic retinopathy (DR) is the most common microvascular complication and leading cause of vision loss in working‑age adults. The retina experiences damage from long‑standing hyperglycemia, resulting in microaneurysms, hemorrhages, lipid exudates and neovascularization[26]. Risk factors for DR include poor glycemic control, hypertension, dyslipidemia, nephropathy, male sex and obesity[27]. Early detection and tight metabolic control are crucial to prevent progression[28]. New insights conceptualize DR as a neurovascular–inflammatory process involving microglial activation and oxidative stress[29].

Diabetic Peripheral Neuropathy

Diabetic peripheral neuropathy (DPN) is the most common neuropathic disorder in people with diabetes. It is characterized by sensory loss, numbness, tingling, burning pain and weakness[30]. Hyperglycemia leads to metabolic and neurovascular changes that damage distal nerve fibers, resulting in loss of protective sensation and risk of ulceration and amputation[31]. Early screening of sensation and monofilament testing is recommended; management includes glycemic control, foot care, pharmacologic treatment of neuropathic pain and education[32].

Macrovascular Complications

Macrovascular complications include coronary artery disease (CAD), cerebrovascular disease and peripheral arterial disease. Patients with T2DM have a 2–4‑fold increased risk of cardiovascular disease. The Yangtze Medicine review notes that about 20–30 % of diabetic patients experience macrovascular complications, which substantially increase morbidity and mortality[33]. Mechanisms involve endothelial dysfunction, oxidative stress, platelet activation, dyslipidemia and hypertension[34]. Atherosclerosis develops more rapidly in diabetic patients, and the interplay between microvascular and macrovascular disease further worsens outcomes[35].

Risk Factors and Screening

Modifiable and Non‑Modifiable Factors

Important risk factors for developing T2DM include:

Age and ethnicity: Advancing age is a strong risk factor; certain ethnic groups (African, Hispanic, Native American, Asian) have higher susceptibility[36]. Family history of diabetes increases risk, reflecting genetic predisposition[36].
Obesity and overweight: Approximately 90 % of patients with T2DM are overweight or obese[37]. Excess adiposity promotes insulin resistance through inflammatory cytokines and adipokines[37].
Physical inactivity: Sedentary lifestyle reduces insulin sensitivity and contributes to weight gain[38].
Dietary patterns: High consumption of processed foods, saturated fats and sugar‑sweetened beverages increases risk, whereas diets rich in whole grains, fruits and vegetables are protective[38].
Gestational diabetes and polycystic ovary syndrome (PCOS): Women with a history of gestational diabetes or PCOS have elevated risk for developing T2DM[36].
Hypertension and dyslipidemia: These metabolic conditions often coexist with diabetes and contribute to insulin resistance and vascular damage[36].
Non‑modifiable factors: Genetic predisposition, ethnicity, family history and age cannot be changed but inform screening strategies[36].

Screening and Diagnostic Criteria

The American Diabetes Association (ADA) recommends screening asymptomatic adults every three years, starting at age 35 or earlier in high‑risk individuals[36]. Diagnostic criteria include[36]:

Fasting plasma glucose (FPG) ≥126 mg/dL (7.0 mmol/L) after at least 8 hours of fasting.
2‑hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during a 75‑g oral glucose tolerance test (OGTT).
Glycated hemoglobin (HbA₁c) ≥6.5 % (48 mmol/mol) on two separate tests.
Random plasma glucose ≥200 mg/dL in a patient with classic symptoms of hyperglycemia.

Individuals with prediabetes meet criteria such as FPG 100–125 mg/dL or HbA₁c 5.7–6.4 %[36].

Nursing Case Presentation

Patient History

Mr. John W., a 55‑year‑old male of African descent, presents to the outpatient clinic for routine evaluation. He was diagnosed with T2DM ten years ago and initially managed with metformin. Over the past five years, he gained 15 kg, with a body mass index (BMI) of 33 kg/m². He works as an accountant, spends most of his day seated, and rarely exercises. He admits to consuming processed foods, sugar‑sweetened beverages and minimal fruits or vegetables. He has a family history of diabetes (father) and hypertension (mother). He smokes one pack per day and occasionally drinks alcohol. Mr. W. reports increased fatigue, blurred vision, tingling in his feet and difficulty healing a minor foot wound.

Past medical history includes hypertension treated with a thiazide diuretic, dyslipidemia treated with a statin and stage II CKD. He had episodes of hyperglycemia requiring emergency care two years ago but denies diabetic ketoacidosis. Medications include metformin 1000 mg twice daily, lisinopril 20 mg daily, hydrochlorothiazide 25 mg daily, atorvastatin 40 mg daily and low‑dose aspirin. He does not regularly monitor his blood glucose at home and has not attended diabetes education classes.

Physical Examination

Vital signs: Blood pressure 152/94 mmHg; heart rate 88 bpm; respiratory rate 16 breaths/min; temperature 36.6 °C; BMI 33 kg/m².
General: Overweight male, alert and oriented; appears fatigued.
Eyes: Mild retinopathy noted on fundoscopic exam microaneurysms and hard exudates. Visual acuity is decreased.
Cardiovascular: Regular rate and rhythm; no murmurs; peripheral pulses palpable but decreased dorsalis pedis pulses.
Respiratory: Clear lungs bilaterally.
Abdomen: Soft, non‑tender; no hepatosplenomegaly.
Extremities: Poor capillary refill; skin is dry; calluses present on soles; a 1‑cm ulcer on the right great toe with surrounding erythema. Sensation decreased in both feet; vibration sense absent.
Neurological: Mild symmetrical distal sensory neuropathy; normal motor strength; absent ankle reflexes.

Laboratory and Diagnostic Tests

Recent laboratory results reveal:

Test	Result	Reference range
Fasting Plasma Glucose	178 mg/dL	70–99 mg/dL
HbA₁c	9.3 %	4.0–5.6 %
Serum Creatinine	1.6 mg/dL	0.6–1.3 mg/dL
Estimated GFR	54 mL/min/1.73 m²	≥ 90 mL/min/1.73 m²
Urine	150 mg/g	< 30 mg/g
Lipid Panel	LDL = 160 mg/dL; HDL = 34 mg/dL; Triglycerides = 240 mg/dL	LDL < 100 mg/dL; HDL > 40 mg/dL (men); TG < 150 mg/dL
Blood Pressure	152/94 mmHg	< 130/80 mmHg

Fundus photography confirms mild non‑proliferative diabetic retinopathy. Monofilament testing indicates loss of protective sensation in both feet. The foot ulcer is assessed using the Wagner classification as Grade 1 (superficial ulcer without infection or ischemia).

Assessment and Nursing Diagnoses

Based on the data collected, the following nursing diagnoses are identified:

Ineffective health management related to inadequate knowledge of disease process, lifestyle modifications and medication adherence, evidenced by elevated HbA₁c, poor dietary habits and lack of self‑monitoring.
Risk for unstable blood glucose level related to inconsistent medication adherence, dietary indiscretion and insufficient physical activity.
Risk for impaired skin integrity related to peripheral neuropathy, vascular insufficiency and foot ulcer.
Risk for infection related to hyperglycemia, foot ulcer and impaired immune response.
Disturbed sensory perception (peripheral neuropathy) related to nerve damage secondary to chronic hyperglycemia[31].
Risk for impaired renal function related to diabetic nephropathy and hypertension[22].

Goals and Outcomes

The primary goals of nursing care include:

Achieve and maintain HbA₁c ≤7 % within six months.
Maintain fasting blood glucose between 80–130 mg/dL and postprandial glucose <180 mg/dL.
Demonstrate correct self‑administration of insulin and oral medications and adherence to treatment regimen.
Describe and implement a nutrition and exercise plan aligned with ADA recommendations.
Identify signs of hypoglycemia and hyperglycemia and actions to take.
Exhibit improved foot care practices and ulcer healing within eight weeks.
Prevent progression of nephropathy and retinopathy through regular monitoring and adherence to treatment.

Evidence‑Based Interventions and Management

Pharmacologic Management

Metformin: Metformin is the first‑line pharmacologic agent for T2DM due to its efficacy, safety, weight neutrality and cardiovascular benefits[39]. It decreases hepatic gluconeogenesis and improves insulin sensitivity[40]. In this case, Mr. W. is already on metformin; the dose should be optimized or titrated to the maximum tolerated dose, considering his renal function.
Sulfonylureas or Glinides: These secretagogues stimulate insulin release but carry the risk of hypoglycemia and weight gain. They may be considered if HbA₁c remains >9 % after metformin[36].
GLP‑1 Receptor Agonists: GLP‑1 receptor agonists increase insulin secretion, suppress glucagon and slow gastric emptying. They promote weight loss and reduce cardiovascular events[41]. Given Mr. W.’s obesity and cardiovascular risk, adding a GLP‑1 RA (e.g., semaglutide) is recommended if accessible.
SGLT2 Inhibitors: These agents promote glycosuria by inhibiting renal glucose reabsorption, leading to improved glycemic control, weight loss, blood pressure reduction and cardiovascular and renal benefits. They are indicated for patients with T2DM and chronic kidney disease[25]. An SGLT2 inhibitor (e.g., empagliflozin) may be added, but careful monitoring of renal function and risk of euglycemic ketoacidosis is necessary.
Insulin Therapy: The ADA recommends initiating basal insulin when HbA₁c >10 % or if the patient has symptomatic hyperglycemia[36]. Mr. W.’s HbA₁c is 9.3 %. If lifestyle and oral therapies fail to achieve glycemic targets, basal insulin (e.g., insulin glargine) should be started. Nurses will teach injection techniques, dosage titration and hypoglycemia prevention.
Antihypertensive and Lipid‑Lowering Agents: Strict control of blood pressure (< 130/80 mmHg) and LDL cholesterol (< 70 mg/dL) reduces cardiovascular risk. ACE inhibitors or angiotensin receptor blockers are preferred for nephroprotection[25]. Atorvastatin dosage may need adjustment to achieve LDL goals; addition of ezetimibe or PCSK9 inhibitor may be considered.
Aspirin: Low‑dose aspirin (75–162 mg/day) is recommended for secondary prevention in patients with established cardiovascular disease. Continue aspirin therapy.

Lifestyle Interventions

Medical Nutrition Therapy (MNT): A registered dietitian will work with Mr. W. to develop a meal plan focusing on whole grains, fruits, vegetables, legumes, nuts and lean proteins[38]. The plan aims for caloric deficit to achieve 5–10 % weight loss over six months, limiting saturated fats and refined carbohydrates. Portion control and carbohydrate counting will be emphasized.
Physical Activity: Mr. W. should engage in at least 150 minutes of moderate‑intensity aerobic exercise per week and include resistance training two to three times weekly[38]. Starting gradually with daily walking and increasing intensity is appropriate.
Weight Management: Weight loss improves insulin sensitivity and glycemic control. Interventions include diet modification, exercise, behavior therapy and potential pharmacologic agents (e.g., GLP‑1 RAs)[37].
Smoking Cessation and Alcohol Moderation: Smoking exacerbates vascular complications and neuropathy. Referral to cessation programs, nicotine replacement or pharmacotherapy may aid quitting. Alcohol intake should be limited.
Diabetes Self‑Management Education (DSME): Nurse‑led DSME improves long‑term glycemic control, self‑efficacy and HDL levels[42]. Educational sessions cover disease pathophysiology, medication administration, blood glucose monitoring, recognition of hypo‑ and hyperglycemia, foot care, stress management and coping strategies. Evidence shows that every 1 % reduction in HbA₁c reduces micro‑ and macrovascular complications by 40 %[42].
Foot Care: Daily foot inspection, proper footwear, moisture control and avoidance of barefoot walking are essential to prevent ulcers. Nurses educate Mr. W. to check for cuts, blisters or signs of infection, and schedule regular podiatric assessments. The existing toe ulcer will be managed using evidence‑based wound care (debridement, moist dressings) and offloading devices.
Retinopathy Screening: Annual dilated eye examinations are necessary to monitor and treat retinopathy promptly[43]. Strict glycemic and blood pressure control can slow progression[28].
Nephropathy Monitoring: Annual assessment of urine albumin and estimated glomerular filtration rate (eGFR) enables early detection of DKD. ACE inhibitors and SGLT2 inhibitors provide renal protection[25].
Neuropathy Management: Neuropathic pain may require medications such as duloxetine, pregabalin or gabapentin. Sensory testing and patient education on foot protection are critical. Referral to a pain specialist may be indicated.
Mental Health Support: Diabetes is associated with depression, anxiety and diabetes distress. Screening and referral to mental health services or support groups can improve adherence and quality of life.

Interdisciplinary Collaboration

Effective management of T2DM requires a multidisciplinary team. Nurses coordinate care with physicians, dietitians, pharmacists, podiatrists, ophthalmologists and mental health professionals. The APA practice guideline for schizophrenia emphasises coordinated specialty care programs for first‑episode psychosis[44]; similarly, chronic disease management benefits from integrated care models. Interdisciplinary collaboration ensures comprehensive assessment, individualized care plans, medication reconciliation, and continuous patient education, thereby optimizing outcomes.

Evaluation and Outcomes

After three months of intensive management, Mr. W.’s HbA₁c decreased to 7.4 %. He reports adherence to his meal plan and exercises five days per week. Weight decreased by 5 kg, and BMI reduced to 31 kg/m². Daily home blood glucose monitoring shows fasting levels around 110 mg/dL and postprandial levels <160 mg/dL. He is comfortable self‑injecting basal insulin and uses a glucometer appropriately. His blood pressure improved to 128/80 mmHg, and lipid profile shows LDL 90 mg/dL and HDL 40 mg/dL.

The foot ulcer healed after eight weeks with proper wound care and offloading. Podiatric follow‑up continues. Mr. W. attends DSME sessions regularly and expresses confidence in managing his diabetes. He quit smoking and uses nicotine patches. He scheduled an annual eye exam, and retinopathy remains stable.

Continued monitoring and adjustments of therapy are necessary. If HbA₁c remains above target, intensification of pharmacologic therapy (e.g., addition of a GLP‑1 RA or SGLT2 inhibitor) will be considered. Regular follow‑up every three months ensures ongoing assessment of glycemic control, renal function, liver function and cardiovascular risk. Encouraging patient engagement and addressing barriers to adherence remain essential components of care.

Discussion

This case highlights the intricate interplay between pathophysiology, lifestyle, comorbidities and social determinants in T2DM. Mr. W. exhibited several risk factors: obesity, sedentary lifestyle, poor diet, smoking, family history and African ancestry. His poor glycemic control led to early microvascular complications retinopathy, nephropathy and neuropathy and a foot ulcer. The global rise of diabetes underscores the importance of primary prevention and early intervention. The WHO notes that lifestyle changes healthy diet, regular physical activity, maintaining a normal weight and avoiding tobacco can prevent or delay T2DM[45].

Pathophysiology: Insulin resistance in skeletal muscle and adipose tissues, along with impaired β‑cell function, constitutes the cornerstone of T2DM. Chronic glucotoxicity, lipotoxicity, inflammatory cytokines and oxidative stress impair insulin signaling and β‑cell survival[13]. The patient’s obesity and sedentary lifestyle contributed to this pathophysiologic milieu. The Endotext chapter emphasises that inappropriate glucagon secretion and incretin defects exacerbate hyperglycemia[16]. In Mr. W.’s case, insulin therapy was added due to inadequate glycemic control with oral agents.

Complications: Microvascular complications occur in a substantial proportion of patients with diabetes. A cross‑sectional study from Ethiopia found that 26.5 % of T2DM patients had microvascular complications with neuropathy being most prevalent[46]. The Yangtze Medicine review highlights that one‑third to one‑half of diabetics experience organ and tissue damage due to microvascular and macrovascular complications[47]. Risk factors for microvascular complications include duration of diabetes, poor glycemic control, hypertension and dyslipidemia[48]. Mr. W. had poorly controlled hypertension and dyslipidemia, further increasing his risk. Early detection through retinal exams, urine albumin tests and sensory testing is critical.

Evidence‑based interventions: The ADA recommends metformin as first‑line therapy[39]. Newer agents such as GLP‑1 RAs and SGLT2 inhibitors provide cardiovascular and renal benefits, aligning treatment with the concept of metabolic dysfunction syndrome (MDS) rather than focusing solely on glycemic control[49]. Nurse‑led DSME improves glycemic control and self‑efficacy[42]. Nurses also play a pivotal role in foot care, medication adherence, lifestyle coaching and psychological support. Comprehensive care extends beyond glycemic targets to include blood pressure, lipid management, weight control, smoking cessation and mental health.

Interdisciplinary care: Collaboration among healthcare professionals improves patient outcomes. Nurses coordinate care, monitor treatment adherence, assess complications, provide education and advocate for the patient. They work with dietitians to develop nutrition plans, pharmacists to optimize medication regimens, podiatrists for foot care, ophthalmologists for retinopathy screening, and mental health providers for psychosocial support. Evidence shows that integrated care models reduce diabetes‑related morbidity and mortality[42].

Public health perspective: Diabetes is both a medical condition and a societal issue. More than half of individuals with diabetes worldwide are not on treatment[2]. Social determinants such as poverty, education, access to healthcare and cultural factors influence disease management. Policy interventions focusing on healthy food environments, physical activity promotion, smoking cessation and equitable healthcare access are necessary to combat the diabetes epidemic.

Conclusion

This case study provides a comprehensive evaluation of a patient with Type 2 diabetes mellitus, emphasizing the importance of pathophysiological understanding, early detection, risk factor modification, and interdisciplinary, evidence‑based management. Diabetes is a global health crisis, with prevalence and mortality increasing worldwide[50]. Pathogenesis involves complex interactions between insulin resistance and β‑cell dysfunction[13]. Chronic hyperglycemia damages microvascular and macrovascular systems, leading to complications such as retinopathy, nephropathy, neuropathy and cardiovascular disease[51]. Risk factors include obesity, physical inactivity, unhealthy diet, hypertension, dyslipidemia, family history and certain ethnicities[36]. Screening and diagnostic criteria (FPG, OGTT, HbA₁c) facilitate early diagnosis[36].

The case of Mr. W. illustrates common challenges: poor adherence, lifestyle factors and social barriers contribute to suboptimal glycemic control and early complications. Evidence‑based interventions comprising optimized pharmacotherapy (metformin, GLP‑1 RAs, SGLT2 inhibitors), lifestyle modification, DSME, foot care, retinopathy screening and nephropathy monitoring help improve outcomes. Nurse‑led programs are particularly effective in educating and empowering patients[42]. Interdisciplinary collaboration ensures holistic care, addressing physical, psychological and social aspects. Ultimately, reducing the global burden of diabetes requires integrating clinical care with public health strategies to promote healthy lifestyles, early screening and equitable access to treatment.

References

American Diabetes Association. (2024). Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement 1), S1–S367. [Diagnostic criteria and risk factors][36].

Bodman, M. A., Dreyer, M. A., & Varacallo, M. A. (2024). Diabetic Peripheral Neuropathy. In StatPearls. StatPearls Publishing. [Etiology, clinical presentation and management of neuropathy][52].

Ciftci, S. N. (2025). Epidemiology and Pathophysiology of Diabetic Retinopathy. In Diabetic Eye Disease – From Pathophysiology to Treatment (pp. 132–149). IntechOpen. [Neurovascular–inflammatory model of DR][53].

Feingold, K. R., Triplitt, C., Cersosimo, E., & DeFronzo, R. A. (2025). Pathogenesis of Type 2 Diabetes Mellitus. In Endotext (online). MDText.com, Inc. [Comprehensive description of T2DM pathophysiology][54].

Gijsen, C. E. W., van Rossem, C., Muris, J. W. M., van Horck, M. W. P., & Dompeling, E. (2024). Improving Asthma Care in Children: Revealing Needs and Bottlenecks Through In‑Depth Interviews. NPJ Primary Care Respiratory Medicine, 34, 42. [Evidence for integrated care models][55].

International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). [Global prevalence and projections][46].

Lu, X., Xie, Q., Pan, X., et al. (2024). Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduction and Targeted Therapy, 9, 262. [Pathogenesis and holistic management][12].

Merid, F., Getahun, F., Esubalew, H., & Gezahegn, T. (2024). Diabetic Microvascular Complications and Associated Factors in Patients with Type 2 Diabetes in Southern Ethiopia. Frontiers in Endocrinology, 15, 1342680. [Prevalence and risk factors for microvascular complications][46].

Mohammed, S., Muhammed, H., Shetty, T., & Shanavas, S. (2025). Micro and Macrovascular Complications in Diabetes Mellitus. Yangtze Medicine, 9, 96–123. [Mechanisms and incidence of vascular complications][56].

Rout, P., & Jialal, I. (2025). Diabetic Nephropathy. In StatPearls. StatPearls Publishing. [Pathology and management of diabetic kidney disease][57].

Shukla, U. V., & Tripathy, K. (2023). Diabetic Retinopathy. In StatPearls. StatPearls Publishing. [Pathogenesis, risk factors and management of DR][58].

StatPearls Publishing. (2026). Type 2 Diabetes. In StatPearls. StatPearls Publishing. [Pathophysiology, screening and treatment recommendations][59].

StatPearls Publishing. (2023). Metformin. In StatPearls. StatPearls Publishing. [First‑line therapy and mechanism of metformin][60].

StatPearls Publishing. (2024). Type 2 Diabetes (Nursing). In StatPearls. StatPearls Publishing. [Nursing management and patient education strategies][61].

Trottier, E. D., Chan, K., Allain, D., & Chauvin‑Kimoff, L. (2021). Managing an Acute Asthma Exacerbation in Children. Paediatrics & Child Health, 26, 438. [Guideline for acute asthma; included to illustrate integrated care models][62].

World Health Organization. (2023). Diabetes Fact Sheet. WHO. [Global statistics, key facts and prevention strategies][63].

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [45] [50] [63] Diabetes